LoadingLoadingLoadingNet selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: both buying and selling, $2K to $30K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
D.E. Shaw
$319.4M
added
Citadel
$282.8M
added
Sells/Trims (1)
Lone Pine
$295.7M
trimmed
Sells (1)
No tracked top-trader positions in MCK as of Oct 21, 17:57 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Financial period
Q1 FY2027
Earnings per share
$9.54 expected
Revenue
$103.74B expected
Estimates as of Oct 21, 2026
EPS expected
$10.53 to $11.26
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $9.93 / $9.54Yahoo Finance | +4.14% beat | $105.38B $103.74B expected | +1.58% beat |
| Mar 31, 2026 | May 7, 2026 | $11.69 / $11.57Yahoo Finance | +1.06% beat | $96.30B No estimate | Unavailable |
| Dec 31, 2025 | Feb 4, 2026 | $9.34 / $9.27Yahoo Finance | +0.71% in line | $106.16B No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $9.86 / $9.05Yahoo Finance | +8.94% beat | $103.15B No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $8.26 / $8.15Alpha Vantage | +1.35% beat | $97.83B No estimate | Unavailable |
| Mar 31, 2025 | May 8, 2025 | $10.12 / $9.83Alpha Vantage | +2.95% beat | $90.82B No estimate | Unavailable |
| Dec 31, 2024 | Feb 5, 2025 | $8.03 / $7.99Alpha Vantage | +0.50% in line | $95.29B No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $7.07 / $6.87Alpha Vantage | +2.91% beat | $93.65B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $103.15B | $106.16B | $96.30B | $105.38B |
| Cost of what it sold | $99.61B | $102.47B | $92.25B | $101.69B |
| Gross profit | $3.54B | $3.69B | $4.04B | $3.69B |
| What it spent | ||||
| Sales and admin | $2.07B | $2.03B | $1.80B | $2.26B |
| Other operating costs | — | $36.0M | — | $102.0M |
| Total operating expenses | $2.07B | $2.07B | $1.80B | $2.37B |
| What was left | ||||
| Operating profit | $1.47B | $1.62B | $2.25B | $1.32B |
| Interest on debt | $74.0M | $63.0M | $61.0M | $77.0M |
| Profit before tax | $1.40B | $1.63B | $2.13B | $1.31B |
| Tax | $232.0M | $380.0M | $270.0M | $276.0M |
| Net profit | $1.11B | $1.19B | $1.68B | $614.0M |
| EBITDA | $1.66B | $1.84B | $2.26B | $1.58B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Leerink raises target for McKesson stock from USD 1,030 to USD 1,070
Leans bullishOct 19McKesson stock trades at EUR 896.00 in weekend trading
Leans bullishOct 18Wells Fargo keeps USD 50.00 target for Omnicell stock
NeutralOct 17McKesson agrees to invest in Option Care Health: what it means for McKesson stock
Leans bullishOct 17McKesson stock: Leerink Partners raises target for McKesson stock to USD 1,070
BullishOct 16Baird lifts target for Cencora stock to USD 373.00
Leans bullishOct 16Leerink raises target for McKesson stock to USD 1,070.00
BullishOct 16Ratification Vote Results: McKesson Members Send a Clear Message – NO!
Leans bearishOct 16
